[Skip to Content]
[Skip to Content Landing]
Views 183
Citations 0
Comment & Response
May 9, 2019

Guidelines for Secondary Solid Cancers Among HSCT Recipients

Author Affiliations
  • 1Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, Azienda Ospedaliera Universitaria, Università degli Studi della Campania “Luigi Vanvitelli,” Naples, Italy
  • 2Department of Internal and Specialty Medicine, Azienda Ospedaliera Universitaria, Università degli Studi della Campania “Luigi Vanvitelli,” Naples, Italy
JAMA Oncol. 2019;5(7):1064. doi:10.1001/jamaoncol.2019.0617

To the Editor We read with interest the cohort study conducted by Tichelli and colleagues1 of patients who developed a second solid cancer (SSC) after a transplant. Hematopoietic stem cell transplant (HSCT) recipients have a considerable risk of developing secondary solid cancers 5 years or more after HSCT owing to factors such as myeloablative total-body irradiation, young age at HSCT, chronic graft-vs-host disease, and prolonged immunosuppressive treatment longer than 24 months.2,3 Therefore, Inamoto et al4 proposed guidelines to help clinicians provide screening and preventive care for secondary cancers among HSCT recipients.

×